Capital Research Global Investors
RYTM icon

Capital Research Global Investors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Capital Research Global Investors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$170M Buy
1,532,303
+416,843
+37% +$37.7M 0.02% 255
2026
Q1 		$97M Buy
1,115,460
+130,374
+13% +$12.7M 0.02% 314
2025
Q4 		$105M Buy
985,086
+386,839
+65% +$41M 0.02% 299
2025
Q3 		$60.4M Buy
+598,247
New +$55.5M 0.01% 337

Other funds holding RYTM

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors's RYTM Position: Q2 2026 in Review

Capital Research Global Investors increased its Rhythm Pharmaceuticals (RYTM) stake by 37% in Q2 2026, buying an estimated $37.7M and bringing the position to 1,532,303 shares worth $170M. The position accounts for 0.02% of the portfolio, ranked #255.

Capital Research Global Investors first reported a position in RYTM in Q3 2025 and has held it in 4 quarters since. 305 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Capital Research Global Investors held 1,532,303 shares of Rhythm Pharmaceuticals worth $170M as of Q2 2026.
  • Capital Research Global Investors bought 416,843 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $37.7M.
  • Rhythm Pharmaceuticals made up 0.02% of Capital Research Global Investors's portfolio in Q2 2026, its #255 holding.
  • Capital Research Global Investors first reported a position in Rhythm Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 305 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Capital Research Global Investors's 13F filing for Q2 2026, filed 12 Aug 2026.